Revance Therapeutics: Cramer’s Top Takeaways

Did you miss “Mad Money” on CNBC? If so, here are some of Jim Cramer’s top takeaways.

In an “Executive Decision” segment, Cramer sat down with Dan Browne, co-founder, president and CEO of Revance Therapeutics (RVNC) , the biotech that’s actively developing an alternative to Allergan’s (AGN) wildly successful Botox.

Browne said that Revance is on track to file for FDA approval for “RT002” next year, which would likely put their product on the market by early 2020. He said what makes RT002 different from Botox is the duration of the dose, which the data is indicating lasts a full six months for frown lines. Revance has plans to explore therapeutic applications for RT002, just like Allergan has.

Browne added that while RT002 is distinctly different from the formulation of Botox, the drug will be made completely in the U.S., which will give his company the same profit margins as their larger rival.

When asked whether they have enough cash on hand to see RT002 to market, Browne said that Revance is well capitalized and they have a number of catalysts ahead that would allow them to raise additional capital if needed.

Cramer and the AAP team are trimming Illinois Tool Works (ITW) and Danaher (DHR) . Find out what they’re telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

Over on Real Money, Cramer says the banks are alive and well. Get more of his insights with a free trial subscription to Real Money.

Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.

To read a full recap of this episode of “Mad Money,” click here.

To watch replays of Cramer’s video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer’s free Booyah! newsletter with all of his latest articles and videos please click here.